Asia Fresh News

Asia Fresh Stories

Archive for December 23rd, 2015

Collaborating With Overseas Universities Improves Reputation and Academic Quality at Esa Unggul University

leave a comment »

JAKARTA, Indonesia/PRNewswire/ — Esa Unggul University, a private university located inJakarta, has undertaken a number of cooperation with various overseas universities to improve its reputation and quality on the basis of academics, learning process, curriculum, and competitive advantages of all graduates. Mr.Arief Kusuma, the rector, explains:The global era is marked by the growth and development of the industry in all aspects of life, as well as the changing needs driven by rapid advances in information technology and communication. Therefore qualified human resources are necessarily required.

Esa Unggul University - Highlights
Esa Unggul University – Highlights

“Education has a vital and strategic role in the development of human resources of the nation and significantly contributes towards economic growth and social transformation. Education will create a literate society which functions as a prerequisite to form a civilized, independent and prosperous society. University as one of the drives of the national development is in charge of educating graduates to have deep and extensive knowledge and skills on local, national and international affairs and are able to compete with the other graduates,” he adds.

The implementation of cooperation with overseas universities is one key factor to succeed in attempting to continuously improve its reputation and quality of education. The overseas universities as mentioned above are as follows:

  1. Nanjing Xiaozhuang University, Mainland China
  2. Nanjing Normal University, Mainland China
  3. North China Electric Power University, Mainland China
  4. The Manila Times College, Philippines
  5. Woosong University, South Korea
  6. Honam University, South Korea
  7. Universiti Kebangsaan Malaysia
  8. Universiti Kuala Lumpur, Malaysia
  9. Mahidol University, Thailand
  10. Burapha University, Thailand
  11. Kasetsart University, Thailand
  12. Saint Louis College, Thailand
  13. Taiwan Asia University, Taiwan
  14. University of Economic and Law Vietnam National University, Vietnam
  15. Tokyo Metropolitan University, Japan
  16. Universite de Technology Compiegne, France
  17. Wales University, UK
  18. Leeds University, UK
  19. University Campus Barnsley, UK
  20. London School of Commerce, UK
  21. George Mason University, USA
  22. Center of International Cooperation of the State University – ESPC, Russian Federation
  23. Moscow State University of Information Technologies, Radio Engineering and Electronics (MIREA), Russian Federation

A lot of benefits can be achieved through this collaboration. Our motto is Working Together Be World Class University. Moreover, realizing the importance of human resources towards the Global Competitiveness and Knowledge Based, international collaboration to expand networking is absolutely necessary,” he proclaims.

About Esa Unggul University

Esa Unggul University as one of the best private universities in Jakarta – Indonesia, has 21 Graduate Study Programs and 5 Post-graduate Study Programs. Its Vision is to be a World Class University based on intellectuality creativity and entrepreneurship. This is corresponding with quality of management and result ofTri Dharma Perguruan Tinggi (Three Commitments of University), namely: Teaching and Learning, Research and Community Service. Its mission is to Organize Qualified and Relevant Education, to Create Convenient Academic Atmosphere, and to Create Characterized and High Competitive Advantage Leaders.

Esa Unggul University
Elistia
elistia@esaunggul.ac.id
Jalan Arjuna Utara No. 09, Kebon JerukWest Jakarta, Indonesia 11510
Website: http://www.esaunggul.ac.id
Phone   : +62-215-674-223

Photo – http://photos.prnasia.com/prnh/20151218/852150867

Source: Esa Unggul University

Written by asiafreshnews

December 23, 2015 at 2:53 pm

Posted in Uncategorized

Sanofi Pasteur’s Dengue Vaccine Approved in the Philippines

leave a comment »

— Dengvaxia®’s first approval in Asia reaffirms company’s vision for priority introduction of the dengue vaccine in endemic countries globally –

LYON, France /PRNewswire/ — Sanofi Pasteur, the vaccines division of Sanofi, announced today that the Philippines have granted marketing approval to Dengvaxia®, making it the first vaccine to be licensed for the prevention of dengue in Asia.

The Philippines’ Food and Drug Administration approved Dengvaxia®, tetravalent dengue vaccine, for the prevention of disease caused by all four dengue types in individuals from 9-45 years of age living in endemic areas.

“Approval of the first dengue vaccine in Asia, which bears 70% of global disease burden[1], is a major milestone in dengue prevention and public health,” notes Olivier Charmeil, President and CEO of Sanofi Pasteur. “Approval of Dengvaxia® in the Philippines, following closely the first approval in Mexico, is further evidence of Sanofi Pasteur’s long-standing commitment to introduce this innovative new vaccine first in countries where dengue is a major public health threat.”

Dengue fever burden in Asia continues to be the highest globally with an estimated 67 million people being sickened by the dengue annually[1]. As an urban disease, dengue attacks populations of Asia in the form of unpredictable outbreaks capable of paralyzing health care systems, negatively impacting social and economic activity. Asian endemic countries spend an estimated 6.5 billion USD annually in both direct medical and indirect costs due to dengue[2].

“Prevention of dengue is an urgent and growing medical priority in the Philippines,” says Dr. May Book Montellano, President, Philippine Foundation for Vaccination. “Vaccination is widely accepted as one of the most cost-effective ways to reduce the spread of infectious diseases like dengue. The approval of Dengvaxia®, the world’s first dengue vaccine, in the Philippines will be a critical addition to the ongoing public education and vector control efforts currently directed towards dengue prevention in our country.”

Dengue is a major public health priority in tropical and subtropical countries in Asia and Latin America. Sanofi Pasteur is introducing Dengvaxia® first in these countries where the vaccine has the greatest potential to reduce dengue burden globally and help to achieve the World Health Organization’s goal to reduce dengue mortality by 50% and morbidity by 25% by 2020 in endemic countries. Sanofi Pasteur enrolled over 40,000 participants in extensive safety and clinical efficacy studies conducted mainly in endemic countries and built a dedicated vaccine production facility in France to secure adequate quality and quantity supply of the vaccine to meet endemic country demand upon introduction.

Dengue disease burden globally

According to the World Health Organization (WHO), dengue is the fastest growing mosquito-borne disease in the world today, causing nearly 400 million infections every year[3]. In the last 50 years dengue has spread from being present in a handful of countries to being endemic in 128 countries, where about 4 billion people live, and dengue incidence has likewise increased 30-fold in this time period[4],[5].

Although dengue affects people from all ages and socio-economic backgrounds, the greatest number of dengue cases worldwide occurs in the highly mobile and social segment of endemic populations that include preadolescents to adult ages of 9 years and above[6].

About Dengvaxia®

Besides the Philippines, Dengvaxia® is also registered in Mexico. Regulatory review processes for Dengvaxia® are continuing in other countries where dengue is a public health priority. Manufacturing of the vaccine has already started in France.

Sanofi Pasteur’s vaccine is the culmination of over two decades of scientific innovation and collaboration, as well as 25 clinical studies in 15 countries around the world. Over 40,000 volunteers participated in the Sanofi Pasteur dengue vaccine clinical study program (phase I, II and III), of whom, 29,000 volunteers received the vaccine. Dengvaxia® successfully completed phase III clinical studies in 2014 to evaluate the primary objective of vaccine efficacy[7],[8]. The Philippines participated in all three phases of the clinical development of Dengvaxia®.

Pooled efficacy and integrated safety analyses from the 25-month Phase III efficacy studies and the ongoing long-term studies, respectively, were published in The New England Journal of Medicine on July 27th 2015 affirming the vaccine’s consistent efficacy and longer-term safety profile in study population 9-16 years of age. In the pooled efficacy analysis in this age group, Dengvaxia® was shown to reduce dengue due to all four serotypes in two-thirds of the participants and prevent 8 out of 10 hospitalizations and up to 93% of severe dengue cases.[9]

Dengvaxia® is the first vaccine licensed for the prevention of dengue in the world. First doses of the vaccine have been produced at the dedicated production site in France with planned full-scale production capacity of 100 million vaccine doses annually.

Additional information about Sanofi Pasteur’s dengue vaccine is available on the web at www.dengue.info.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York(NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers a broad range of vaccines protecting against 20 infectious diseases. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year endedDecember 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

[1]

Nature. 2013 Apr 25;496(7446):504-7

[2]

Shepard DS, Halasa YA, Undurraga EA, Stanaway J. Global economic cost of dengue illness. Poster presented at: American Society of Tropical Medicine and Hygiene Annual Meeting; Oct. 25-29, 2015, Philadelphia, PA, Poster 781

[3]

WHO. Dengue and severe dengue. Fact Sheet N° 117. May 2015 http://www.who.int/mediacentre/factsheets/fs117/en/

[4]

Ibid.

[5]

WHO. Emergencies, preparedness, response. Impact of dengue http://www.who.int/csr/disease/dengue/impact/en/

[6]

Joseph R. Egger, Paul G. Coleman. Age and Clinical Dengue Illness. Emerg Infect Dis. 2007 June; 13(6): 924–927.

San Martin JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg 2010;82:128-35.

[7]

Capeding M.R. et.al, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial ; Volume 384, Issue 9951, 11–17 October 2014, Pages 1358–1365.

[8]

Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015.

[9]

Hadinegoro, Sri Rezeki S., et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease Integrated Analysis of Efficacy and Interim Long-Term Safety Data for a Dengue Vaccine in Endemic Regions. July 27, 2015DOI: 10.1056/NEJMoa1506223.

Source: Sanofi Pasteur

Related stocks: EuronextParis:SAN NYSE:SNY

Written by asiafreshnews

December 23, 2015 at 2:22 pm

Posted in Uncategorized

Sukanto Tanoto Inaugurates Forestry Knowledge Hub Tanoto Forestry Information Center

leave a comment »

BOGOR, Indonesia /PRNewswire/ — A new knowledge hub for forestry management and science has been established at the Bogor Agricultural University. The Tanoto Forestry Information Center (TFIC) was inaugurated today by Sukanto Tanoto, Founder and Chairman of Tanoto Foundation board of trustees.

Tanoto Foundation founder Sukanto Tanoto inaugurates the Tanoto Forestry Information Center, which aims to be a knowledge hub for forestry management and science.
Tanoto Foundation founder Sukanto Tanoto inaugurates the Tanoto Forestry Information Center, which aims to be a knowledge hub for forestry management and science.

The Center will act as a knowledge incubator with resources for research and seminars, as well as connect the university with other universities and research institutions globally. The three-storey building, with 1,500 square meters floor area, provides access to international journals and is open to the public. TFIC visitors may also access the university’s library as well as various multimedia resources on forestry information.

Sukanto Tanoto, also RGE‘s Chairman, said: “The Center is one of our initiatives to support the development of forestry science in Indonesia. We look forward to wider collaboration with the Bogor Agricultural University and other universities and research institutions to further develop research and development.”

Bogor Agricultural University’s Rector Herry Suhardiyanto said: “With TFIC’s establishment, we can have national policies which are based on scientific research and findings. We also hope that the Center will foster more research in the area of forestry management.”

According to the Forestry Statistics of Indonesia published by the Ministry of Forestry in September 2013, 52.3% or 99.6 million hectares of Indonesia are forests. Of the 4,000 types of trees found, 267 have high economic value. More than 3.76 million people work in the forestry sector, contributing around USD 21 billion, or 3.5% of Indonesia’sGDP.

A respected business leader with pioneering success in the plywood and forestry industry, 66-year old Sukanto Tanoto said: “The forestry industry is crucial to Indonesia’s economy. To improve the sector’s contribution,Indonesia needs people knowledgeable in forestry. These are the people who can use and develop applicable knowledge. We hope the Tanoto Forestry Information Center will produce prominent scientists and practitioners of sustainable forestry at the national and international levels.”

The inauguration event was attended by staff, students, and alumni of the Bogor Agricultural University, representatives from the Ministry of Research Technology and Higher Education and the Ministry of Forestry and Environment, various NGOs, and representatives from Royal Golden Eagle (RGE) business groups.

The TFIC is the culmination of a longstanding collaboration between the Bogor Agricultural University and Tanoto Foundation since 2006. Tanoto Foundation has, to date, disbursed more than 400 scholarships to undergraduate and graduate students of the university.

About Tanoto Foundation

Web: www.tanotofoundation.org
Twitter: @tanotoeducation
LinkedIn: https://www.linkedin.com/company/1825074
Facebook: https://www.facebook.com/tanotofoundation/

Photo – http://photos.prnasia.com/prnh/20151222/8521508763

Source: Tanoto Foundation

Written by asiafreshnews

December 23, 2015 at 12:32 pm

Posted in Uncategorized

Veritas Technologies Named a “Leader” in the 2015 Gartner Magic Quadrant for Enterprise Information Archiving

leave a comment »

-Veritas Placed in “Leader” Category for 12th Consecutive Year

SINGAPORE /PRNewswire/ — Veritas Technologies LLC, a global leader in information management solutions today announced its place as a “Leader” in Gartner’s 2015 Magic Quadrant for Enterprise Information Archiving (EIA) for the 12thconsecutive year.

Gartner evaluated vendors offering products and services that provide archiving for email, social media, files on file share services and other content types, including structured data. Veritas was recognized for its blend of compliance, e-discovery and retention management services with Enterprise Vault acknowledged as a leading product for capturing email content.

“It is an honor to be placed again in the ‘Leader’ Category,” said Greg Muscarella, Senior Vice President, Information Intelligence, Veritas. “This recognition from Gartner is a reflection of our continued innovation and focus on addressing customers’ toughest challenges with unstructured data and managing critical information assets. As we approach becoming an independent company, we are committed to anticipating emerging trends and offering solutions that empower our customers to gain new insights from their data assets.”

Veritas’ Enterprise Vault solutions empower organizations to store, manage and discover critical business information through archiving and e-discovery capabilities. The solutions can pull enterprise data from across the datacenter and index, compress and deduplicate data to reduce storage space and expenses. Enterprise Vault.cloud has also recently added upgraded capabilities for e-discovery including search, tagging, legal hold, export and review.

What Makes a “Leader”?

Gartner Magic Quadrant “Leaders” have the highest combined measures of Ability to Execute and Completeness of Vision. Gartner looks for companies that have the most comprehensive and scalable product portfolios as well as a proven track record of financial performance and an established market presence. “Leaders” are innovative and forward-looking, anticipating market trends and remaining nimble in a changing industry. Veritas is one of six “Leaders” in this Magic Quadrant. Access the full report here.

About Veritas Technologies LLC

Veritas Technologies LLC enables organizations to harness the power of their information, with solutions designed to serve the world’s largest and most complex heterogeneous environments. Veritas works with 86 percent of Fortune 500 companies today, improving data availability and revealing insights to drive competitive advantage.
www.veritas.com

Veritas, the Veritas Logo, and NetBackup are trademarks or registered trademarks of Veritas Technologies LLC or its affiliates in the U.S. and other countries. Other names may be trademarks of their respective owners.

CONTACTS:

Belinda Lim
Corporate Communications
Veritas Technologies
+65-6413-4306
belinda.lim@veritas.com

Asuka Nagai
Corporate Communications
Veritas Technologies
+81-3-4531-1753
asuka.nagai@veritas.com

Victoria Lim/ Venessa Ho
Text100 Singapore
+65-6603-9000
veritas@text100.com.sg

Logo – http://photos.prnasia.com/prnh/20150408/8521502200

Source: Veritas
Related Links:

Written by asiafreshnews

December 23, 2015 at 12:30 pm

Posted in Uncategorized

Samsung BioLogics to Construct World’s Largest Biopharmaceutical Manufacturing Plant

leave a comment »

— 850 billion won to be invested in the 180,000-liter plant
— Poised to become the Global CMO Leader by 2018

SEOUL, South Korea /PRNewswire/ — Samsung BioLogics today celebrated the groundbreaking of its third plant in Incheon Free Economic Zone, Songdo, Korea. Joining the event were Samsung Electronics Vice Chairman Jay Y. Lee, Samsung BioLogics President & CEO Dr. TH Kim and over 500 attendees.

Samsung BioLogics to Construct World's Largest Biopharmaceutical Manufacturing Plant
Samsung BioLogics to Construct World’s Largest Biopharmaceutical Manufacturing Plant

With a total investment of 850 billion won, the third plant will be a world-leading facility both in terms of capacity (180,000 liters) and production efficiency. The plant is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation.

Once it begins operation, Samsung BioLogics expects to become the world’s largest biologics contract manufacturing organization (CMO) with a total production capacity of 360,000 liters.

“We are investing in a third plant to provide a stable supply of biopharmaceuticals, a market which is growing exponentially, and to meet the manufacturing demands from global biopharmaceutical companies,” said Dr. TH Kim, CEO of Samsung BioLogics. “With the world’s largest capacity and the capability to operate 365 days a year non-stop, the third plant will boast world-class quality and productivity. ”

Once the third plant is in full operation, Samsung BioLogics expects it will be able to reach 2 trillion won in annual sales and 1 trillion won in operating profit. In the longer term, the company plans to continuously expand its CMO business with further investments planned for 4th and 5th plants.

Samsung BioLogics’ first plant has recently received official approval for production from the U.S. Food and Drug Administration, and its second plant is scheduled to begin operation in early 2016.

Photo – http://photos.prnasia.com/prnh/20151221/8521508691

Source: Samsung BioLogics

Written by asiafreshnews

December 23, 2015 at 10:24 am

Posted in Uncategorized